Health & Environmental Research Online (HERO)


Print Feedback Export to File
2734970 
Journal Article 
BCNU in the treatment of advanced Hodgkin's disease 
Cipriani, D; Strinchini, A 
1972 
1 
The Lancet
ISSN: 0140-6736
EISSN: 1474-547X 
IPA/73/067050 
VOL 1 ISS Jun 17 1972 
REF 
English 
IPA COPYRIGHT: ASHP Poor results were obtained when 11 patients with Hodgkin's disease were treated with BCNU (carmustine). The initial treatment was given I.V. at the dosage of 100 mg./m.2/day on 2 successive days. The maintenance dosage was 100 mg./m.2 once a month. Two patients had complete remission lasting 3 to 12 weeks; partial remission was obtained in 3 cases (1 patient for 4 months and the remaining 2 patients for 1 month). No remission was obtained in the remaining 6 patients.